Switching from Metoprolol Tartrate to Carvedilol in HFrEF with Persistent AFib Post-CABG
Rationale for Switching
- The American Heart Association recommends carvedilol as one of the three beta-blockers proven to reduce mortality in HFrEF patients, along with bisoprolol and sustained-release metoprolol succinate 1, 3
- The European Society of Cardiology specifically recommends bisoprolol, carvedilol, sustained-release metoprolol succinate, or nebivolol for patients with HFrEF 4
Protocol for Safe Switching
- The American College of Cardiology recommends confirming patient is hemodynamically stable (systolic BP >90 mmHg, heart rate >60 bpm) before switching from metoprolol tartrate to carvedilol 2
- The European Society of Cardiology recommends ensuring patient is not in decompensated heart failure before switching from metoprolol tartrate to carvedilol 2
- Baseline renal function, potassium levels, and liver function should be checked before switching from metoprolol tartrate to carvedilol, as recommended by the American Heart Association 3
Special Considerations for Post-CABG Patients with AFib
- The American College of Cardiology recommends ensuring adequate rate control (resting heart rate <80 bpm) for patients with persistent AFib 2
- The European Society of Cardiology recommends maintaining appropriate anticoagulation based on CHA₂DS₂-VASc score for patients with persistent AFib 2
Monitoring Parameters
- The American Heart Association recommends monitoring heart rate and blood pressure at each dose titration, as well as signs and symptoms of worsening heart failure 2, 5
- Renal function and electrolytes, particularly in patients on concomitant RAAS inhibitors, should be monitored, as recommended by the American Heart Association 3
- An ECG should be performed to assess rate control in persistent AFib, as recommended by the American College of Cardiology 6